The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Reconsidering the cutoff between sensitive and refractory relapses in extensive-stage small cell lung cancer in the era of immunotherapy.
 
Masahiro Torasawa
No Relationships to Disclose
 
Hidehito Horinouchi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); AstraZeneca (Inst); BMKK (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Shogo Nomura
Employment - Asahi Kasei (I)
Honoraria - AstraZeneca; Bayer; Chugai Pharma; Kyowa Hakko Bio
Research Funding - Amgen Astellas BioPharma (Inst); AstraZeneca (Inst)
 
Satoshi Igawa
No Relationships to Disclose
 
Maiko Asai
No Relationships to Disclose
 
Hidenobu Ishii
Honoraria - AMCO; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Merck Serono; MSD Oncology
 
Hiroshi Wakui
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyouwa Kirin; Lilly; MSD; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; UCB
 
Ryota Ushio
No Relationships to Disclose
 
Tetsuhiko Asao
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Merck; Merck Serono; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Nippon Boehringer Ingelheim
 
Yukiko Namba
Employment - MSD K.K (I)
 
Ryo Koyama
No Relationships to Disclose
 
Isana Katayama
No Relationships to Disclose
 
Hironari Matsuda
No Relationships to Disclose
 
Shinichi Sasaki
Consulting or Advisory Role - Daiichi Sankyo Company, Ltd.
Research Funding - Shionogi (Inst)
 
Kazuhisa Takahashi
Honoraria - Amgen; AstraZeneca; Bristol-Myers K. K.; Chugai Pharma; DAIICHI SANKYO Co., LTD.; Eisai; Kyorin; Lilly Japan; MSD K. K.; Nippon Boehringer Ingelheim; Nippon Kayaku; Nobelpharma; Novartis; Ono Pharmaceutical; Sawai Pharmaceutical Co; Shionogi; Taiho Pharmaceutical; Takeda; Viatris
Speakers' Bureau - Chugai Pharma; Kyorin; Novartis
Research Funding - AstraZeneca; Bayer Yakuhin; Bristol-Myers K. K.; Chugai Pharma; Janssen; Janssen; MSD K. K.; Ono Pharmaceutical
 
Yukio Hosomi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin International; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Katsuhiko Naoki
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Nippon Boehringer Ingelheim
Research Funding - Chugai Pharma; Nippon Boehringer Ingelheim; Ono Pharmaceutical; PAREXEL; Taiho Pharmaceutical
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Janssen (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)